47.1 Early Pregnancy Diagnosis, Dating & Initial Complications

Pregnancy Diagnosis & Human Chorionic Gonadotropin (hCG) Kinetics

Confirmation of pregnancy relies on the biochemical detection of human chorionic gonadotropin (hCG), a heterodimeric glycoprotein hormone produced by embryonic syncytiotrophoblastic cells following blastocyst implantation. The hormone consists of an alpha subunit (structurally identical to luteinizing hormone [LH], follicle-stimulating hormone [FSH], and thyroid-stimulating hormone [TSH]) and a unique beta subunit (beta-hCG), which confers specific biological and immunologic activity.

Qualitative Urine hCG Testing

• Sensitivity Threshold: Standard point-of-care qualitative urine tests utilize enzyme-linked immunosorbent assays (ELISA) or lateral flow immunochromatography with a detection threshold of 20 to 25 mIU/mL of beta-hCG.
• Timing: Urine hCG typically turns positive approximately 8 to 10 days after conception (around 3 to 4 weeks after the Last Menstrual Period [LMP] in a standard 28-day cycle), corresponding to the first day of the missed menstrual period.
• Clinical Nuances & False Results:
  • First Morning Void: Recommended for testing because overnight urine concentration maximizes test sensitivity. Dilute urine (specific gravity <1.005) secondary to high fluid intake can produce a false-negative result in very early gestation.
  • False Negatives & The "Hook Effect": The "hook effect" (prozone phenomenon) occurs when extraordinarily high concentrations of beta-hCG (frequently seen in complete hydatidiform molar pregnancy or multiple gestations, typically >500,000 mIU/mL) oversaturate both the fixed capture antibodies and mobile tracer antibodies independently. This prevents antibody-antigen-antibody sandwich complex formation, yielding a paradoxically faint or false-negative result. When a molar pregnancy is clinically suspected but urine testing is negative or faintly positive, serial manual dilution of the urine specimen resolves the hook effect and unmasks the true positive result.
  • False Positives: Rare (<1%), caused by heterophile antibodies, severe proteinuria, gross hematuria, exogenous hCG administration for assisted reproduction, pituitary hCG production in perimenopausal/postmenopausal women, or hCG-secreting germ cell tumors.

Quantitative Serum Beta-hCG Dynamics

• Sensitivity: Serum assays can detect beta-hCG concentrations as low as 1 to 2 mIU/mL.
• Kinetics in Viable Intrauterine Pregnancy (IUP):
  • In a normal, viable early gestation (<6 to 7 weeks), circulating beta-hCG concentrations increase exponentially. Although historical teaching emphasized a "doubling every 48 hours," extensive prospective clinical data define a minimum acceptable rise of 35% to 50% over 48 hours (specifically: >=49% for baseline hCG <1,500 mIU/mL; >=40% for baseline 1,500 to 3,000 mIU/mL; and >=35% for baseline >3,000 mIU/mL).
  • Serum beta-hCG peaks at approximately 8 to 11 weeks of gestation (reaching 100,000 to 200,000 mIU/mL) before plateauing and declining to a steady plateau of approximately 10,000 to 20,000 mIU/mL throughout the second and third trimesters.
• Abnormal hCG Kinetics:
  • Suboptimal Rise (<35% in 48 hours): Highly suspicious for an abnormal gestation—either an ectopic pregnancy or an impending non-viable early pregnancy loss (miscarriage).
  • Plateauing Levels: Characteristically seen in ectopic pregnancies where surviving extrauterine trophoblastic tissue produces a flat hCG trajectory.
  • Declining Levels: Indicates a non-viable pregnancy (spontaneous abortion or spontaneously resolving ectopic pregnancy).

---

Gestational Dating: Naegele's Rule vs. First-Trimester Ultrasound

Accurate gestational dating is paramount in obstetric care because all subsequent prenatal screenings, growth assessments, post-term inductions, and viability decisions hinge upon the established Estimated Due Date (EDD).

Naegele's Rule for Calculating EDD

• Formula: $\text{EDD} = \text{First Day of LMP} + 7 \text{ Days} - 3 \text{ Months} + 1 \text{ Year}$
• Physiologic Assumptions & Pitfalls:
  • Assumes a strictly regular 28-day menstrual cycle with ovulation and fertilization occurring precisely on Cycle Day 14.
  • Inaccuracies: Naegele's rule is inherently unreliable in patients with:
    1. Irregular or oligomenorrheic menstrual cycles (e.g., polycystic ovary syndrome);
    2. Recent discontinuation of hormonal contraception within the preceding 3 months (delayed return of ovulation);
    3. Conception during lactational amenorrhea;
    4. First-trimester vaginal bleeding or implantation spotting mistaken for a normal menses.

Crown-Rump Length (CRL) & Sonographic Dating Guidelines

[!IMPORTANT] GOLD STANDARD OF GESTATIONAL DATING First-trimester transvaginal ultrasound measurement of the Crown-Rump Length (CRL) is the single most accurate method for establishing or confirming gestational age, carrying an accuracy margin of +/- 5 to 7 days.

               ACOG GESTATIONAL DATING DISCREPANCY RE-ASSIGNMENT THRESHOLDS

   Gestational Age at TVUS    Method of Measurement    Discrepancy (LMP vs. US)    Action Mandated
   ═══════════════════════════════════════════════════════════════════════════════════════════════════
   <= 8 6/7 weeks            Crown-Rump Length (CRL)  > 5 days                   Change EDD to US date
   
   9 0/7 to 13 6/7 weeks     Crown-Rump Length (CRL)  > 7 days                   Change EDD to US date
   
   14 0/7 to 15 6/7 weeks    BPD, HC, AC, FL          > 7 days                   Change EDD to US date
   
   16 0/7 to 21 6/7 weeks    BPD, HC, AC, FL          > 10 days                  Change EDD to US date
   
   >= 22 0/7 weeks           BPD, HC, AC, FL          > 14 to 21 days            Change EDD to US date
   ═══════════════════════════════════════════════════════════════════════════════════════════════════
   Clinical Rule: If the discrepancy is LESS THAN OR EQUAL TO the threshold, KEEP the LMP date!

• Technique: The CRL measures the longest straight-line distance from the top of the embryonic head (crown) to the outer curvature of the breech (rump), excluding the yolk sac and fetal extremities. It is applicable up to a CRL of 84 mm (corresponding to approximately 13 6/7 weeks).

---

The Transvaginal Ultrasound Discriminatory Zone & Pregnancy of Unknown Location

The discriminatory zone is defined as the serum quantitative beta-hCG concentration above which a normal intrauterine gestational sac must reliably be visualized within the endometrial cavity by transvaginal ultrasound (TVUS).

Defining the Discriminatory Zone

• Standard Threshold: Historically established between 1,500 and 2,000 mIU/mL (using the Third International Standard). However, current American College of Obstetricians and Gynecologists (ACOG) and Society of Radiologists in Ultrasound guidelines recommend utilizing a conservative threshold of up to 3,500 mIU/mL.
• Clinical Rationale for 3,500 mIU/mL: Setting the discriminatory threshold higher prevents the catastrophic misdiagnosis of a viable, desired early intrauterine pregnancy (such as a multiple gestation or delayed conception) as an ectopic pregnancy, thereby avoiding inadvertent administration of teratogenic methotrexate or diagnostic uterine evacuation.

Sonographic Milestones of Early Intrauterine Gestation

1. Gestational Sac (4.5 to 5.0 weeks): Round or oval hypoechoic fluid collection eccentrically positioned within the thickened decidua. Demonstrates the "intradecidual sign" or "double decidual sac sign" (two concentric echogenic rings surrounding the fluid collection).
2. Yolk Sac (5.0 to 5.5 weeks): A round, thin-walled, hyperechoic ring within the gestational sac. The yolk sac is the first definitive sonographic confirmation of an intrauterine pregnancy, reliably distinguishing a true gestation from the central, amorphous "pseudogestational sac" (fluid/blood collection) often seen in ectopic pregnancies.
3. Embryo & Fetal Cardiac Motion (5.5 to 6.0 weeks): A linear echogenic thickening adjacent to the yolk sac. Rhythmic embryonic cardiac flicker must be visualized once the CRL reaches >= 7 mm.

                     EARLY PREGNANCY SONOGRAPHIC MILESTONES

   Gestational Age     Serum beta-hCG (approx)     First Visible Structure on TVUS
   ═══════════════════════════════════════════════════════════════════════════════════════════════════
   4.5 to 5.0 Weeks    1,500 to 2,000 mIU/mL       Gestational Sac (Double decidual sign)
   5.0 to 5.5 Weeks    3,000 to 5,000 mIU/mL       Yolk Sac (Confirms IUP; rules out pseudosac)
   5.5 to 6.0 Weeks    > 5,000 to 10,000 mIU/mL    Embryonic Pole with Cardiac Flicker (FHR)
   ═══════════════════════════════════════════════════════════════════════════════════════════════════

Pregnancy of Unknown Location (PUL)

• Definition: A clinical scenario in which a patient has a positive qualitative urine or serum beta-hCG test, but high-resolution TVUS demonstrates neither an intrauterine pregnancy nor an extrauterine adnexal mass/ectopic gestation.
• Diagnostic Management Algorithm:
  • If beta-hCG is <3,500 mIU/mL and patient is hemodynamically stable without peritoneal signs:
    • Re-evaluate serum quantitative beta-hCG in exactly 48 hours using the identical laboratory platform.
    • If beta-hCG rises appropriately (>=35-50%): Repeat TVUS when the discriminatory threshold (>2,000 to 3,500 mIU/mL) is achieved.
    • If beta-hCG plateaus or rises suboptimally (<35%): Presume non-viable pregnancy (high suspicion for ectopic pregnancy).
    • If beta-hCG decreases by >50%: Consistent with a spontaneously resolving failing pregnancy (early miscarriage or resolving ectopic); track serial hCG weekly to <5 mIU/mL.
  • If beta-hCG is >=3,500 mIU/mL and the uterine cavity is completely empty:
    • Highly indicative of an ectopic pregnancy (or a completely expelled miscarriage). Proceed immediately with targeted ectopic evaluation and intervention.

---

Ectopic Pregnancy: Anatomy, Epidemiology & Risk Stratification

An ectopic pregnancy occurs when a fertilized blastocyst implants outside the functional endometrium of the uterine cavity. Ectopic pregnancy accounts for 1% to 2% of all pregnancies in the United States but remains the leading cause of first-trimester pregnancy-related maternal mortality, primarily due to catastrophic intra-abdominal hemorrhage.

Anatomical Distribution of Ectopic Implantation

• Fallopian Tube (>95% of cases):
  • Ampulla: 70% to 80% (most common location due to widest luminal caliber and site of fertilization).
  • Isthmus: 12% (narrow lumen, prone to early rupture at 6 to 8 weeks).
  • Fimbriae (infundibulum): 5% to 10%.
  • Interstitial / Cornual: 2% to 3%.
    • Clinical Critical Pearl: Interstitial pregnancies implant in the intramural segment of the fallopian tube surrounded by myometrium. Because the myometrium can stretch, these pregnancies often remain unruptured until 8 to 16 weeks of gestation. When rupture eventually occurs, proximity to the ascending uterine artery branches produces sudden, massive, and rapidly fatal cataclysmic hemorrhage.
• Non-Tubal Sites (<5% of cases):
  • Ovarian (3%);
  • Cesarean scar defect (isthmocele; 1% to 2%);
  • Cervical (1%);
  • Abdominal cavity (1%).

Major Risk Factors

                  RISK STRATIFICATION FOR ECTOPIC PREGNANCY

   Risk Category       Risk Factor                                     Relative Risk / Odds Ratio
   ═══════════════════════════════════════════════════════════════════════════════════════════════════
   HIGH RISK           Prior Ectopic Pregnancy (STRONGEST FACTOR)     Recurrence OR: 3.0 to 13.0
                       (10-15% after 1 ectopic; >25% after >=2)       
                       Prior Fallopian Tube Surgery / Tubal Ligation   OR: 9.0 to 21.0
                       Documented Tubal Pathology / Hydrosalpinx       OR: 3.5 to 4.0
                       In Situ Intrauterine Device (IUD)*             OR: 4.5 to 10.0
   
   MODERATE RISK       History of Pelvic Inflammatory Disease (PID)   OR: 2.5 to 3.5
                       History of Infertility / Assisted Reproduction  OR: 2.5 to 3.0
                       Multiple Sexual Partners / STIs (Chlamydia)    OR: 2.0 to 3.0
   
   MILD / OTHER        Cigarette Smoking (>20 cigarettes/day)          OR: 1.5 to 2.5
                       Previous Pelvic / Abdominal Surgery            OR: 1.5 to 2.0
   ═══════════════════════════════════════════════════════════════════════════════════════════════════
   *Note on IUDs: IUDs are highly effective contraceptives that dramatically lower the overall
   absolute rate of pregnancy. However, if an accidental conception occurs with an IUD in situ,
   up to 30% to 50% of those pregnancies are ectopic!

The Cardinal Clinical Triad

1. Amenorrhea or Delayed Menses (frequently with a history of missed period 6 to 8 weeks prior);
2. Abdominal / Pelvic Pain (present in >95% of symptomatic cases; typically unilateral, sharp, or dull ache);
3. Vaginal Bleeding or Spotting (present in 60% to 80%; typically dark brown or intermittent due to sloughing of decidualized endometrium from inadequate hCG support).

Clinical Presentation of Tubal Rupture

Tubal rupture represents a surgical catastrophe characterized by:

• Sudden, tearing, excruciating lower abdominal and pelvic pain;
• Kehr Sign: Referred sharp pain to the ipsilateral shoulder tip caused by subdiaphragmatic blood collection irritating the phrenic nerve (C3-C5 distribution);
• Peritoneal irritation: Involuntary guarding, rebound tenderness, and marked abdominal rigidity;
• Hemodynamic shock: Hypotension, narrow pulse pressure, tachycardia, diaphoresis, syncope, or altered mental status.

---

Medical vs. Surgical Management of Ectopic Pregnancy

Once an ectopic pregnancy is identified, management involves medical therapy with methotrexate or surgical intervention via laparoscopy or laparotomy.

Medical Therapy: Methotrexate (MTX)

Methotrexate is a structural folate analogue that competitively inhibits dihydrofolate reductase (DHFR), preventing the conversion of dihydrofolate to tetrahydrofolate. This disrupts purine and thymidylate nucleotide synthesis, arresting DNA replication, RNA synthesis, and cell proliferation in rapidly dividing trophoblastic tissues.

                     METHOTREXATE CANDIDACY & SELECTION CRITERIA

   Strict Eligibility Criteria (ALL MUST BE MET)        Absolute Contraindications
   ═══════════════════════════════════════════════════════════════════════════════════════════════════
   1. Hemodynamically stable; no active hemorrhage      • Hemodynamic instability / ruptured tubal mass
   2. Unruptured adnexal mass <= 3.5 cm diameter        • Positive embryonic cardiac activity on TVUS
   3. Absence of embryonic cardiac motion on TVUS       • Baseline serum beta-hCG > 5,000 mIU/mL (relative)
   4. Baseline serum beta-hCG < 5,000 mIU/mL            • Intrauterine pregnancy (desired or unexcluded)
   5. Normal renal function (creatinine, BUN)           • Renal insufficiency (serum Cr > 1.3 mg/dL)
   6. Normal hepatic enzymes (AST, ALT < 2x ULN)        • Active liver disease or chronic alcoholism
   7. Normal baseline hematology (no leukopenia/thromb) • Immunodeficiency / active pulmonary disease
   8. Patient willing and able to comply with follow-up • Breastfeeding; allergy/hypersensitivity to MTX
   ═══════════════════════════════════════════════════════════════════════════════════════════════════

Methotrexate Dosing & The Single-Dose Protocol

• Dosage: 50 mg/m² body surface area (BSA) administered intramuscularly (IM) as a single dose.
• Required Baseline Labs: Quantitative beta-hCG, Type and Screen (with Rh status), Complete Blood Count (CBC), Comprehensive Metabolic Panel (hepatic transaminases, BUN, creatinine).

               METHOTREXATE SINGLE-DOSE PROTOCOL MONITORING TIMELINE

   Protocol Day     Action / Laboratory Test                Expected Pattern & Clinical Decision
   ═══════════════════════════════════════════════════════════════════════════════════════════════════
   Day 1            Administer Methotrexate 50 mg/m² IM      Establish baseline quantitative beta-hCG.
   
   Day 4            Measure serum quantitative beta-hCG      beta-hCG commonly INCREASES or plateaus
                                                            due to trophoblast lysis. Do not panic!
   
   Day 7            Measure serum quantitative beta-hCG      MANDATORY CRITERION: beta-hCG must
                                                            DECREASE BY >= 15% from Day 4 to Day 7.
   
   Post-Day 7       Weekly serum quantitative beta-hCG       If >=15% drop achieved: track weekly until
                                                            completely undetectable (<5 mIU/mL).
                                                            If <15% drop: give 2nd MTX dose (50 mg/m²)
                                                            on Day 7 OR proceed to surgical exploration.
   ═══════════════════════════════════════════════════════════════════════════════════════════════════

• Patient Counseling During MTX Therapy:
  • Discontinue all folic acid-containing supplements and prenatal vitamins (folate directly overcomes MTX enzyme inhibition);
  • Avoid NSAIDs (aspirin, ibuprofen, naproxen), as NSAIDs decrease renal blood flow and competitive tubular clearance of MTX, increasing toxic drug exposure;
  • Avoid alcohol (hepatotoxicity risk);
  • Avoid vigorous physical exercise, heavy lifting, and sexual intercourse until hCG clears (reduces risk of mechanical rupture of the weakened fallopian tube);
  • Avoid prolonged direct sunlight exposure (photosensitivity dermatologic reaction);
  • "Separation Pain": 50% of patients experience transient, mild-to-moderate lower quadrant abdominal cramping between Days 2 and 5 post-injection secondary to tubal abortion and hematoma formation. It must be differentiated from true tubal rupture (rupture is accompanied by peritoneal signs, syncope, tachycardia, or severe hypotension).

Surgical Management

• Indications: Hemodynamic instability, suspected or confirmed tubal rupture, peritoneal signs, adnexal mass >3.5 cm, visible embryonic cardiac activity on ultrasound, initial serum beta-hCG >=5,000 mIU/mL, contraindications to methotrexate, or failed medical management.
• Surgical Approaches:
  • Laparoscopic Salpingectomy: Complete resection of the affected fallopian tube. Preferred procedure in cases of extensive tubal destruction, recurrent ectopic pregnancy in the same tube, completed childbearing, or uncontrolled hemorrhage.
  • Laparoscopic Salpingostomy: Linear longitudinal incision along the antimesenteric border of the fallopian tube over the ectopic implantation, evacuation of the products of conception, and preservation of the tube (heals by secondary intention). Indicated in patients desiring future fertility who possess a compromised or absent contralateral fallopian tube. Requires postoperative weekly beta-hCG monitoring until zero to rule out persistent trophoblastic tissue (occurs in 5-10% of salpingostomies; treated with a single dose of prophylactic MTX).
  • Emergent Exploratory Laparotomy: Indicated in patients presenting in profound, uncorrectable hemorrhagic shock with massive hemoperitoneum.

---

The Spontaneous Abortion (Miscarriage) Spectrum

Early pregnancy loss is defined as the spontaneous demise of an intrauterine pregnancy prior to 20 0/7 weeks of gestation. Approximately 10% to 20% of clinically recognized pregnancies end in spontaneous abortion, with >80% occurring during the first 12 weeks (first trimester). Sporadic chromosomal anomalies—predominantly autosomal trisomies (trisomy 16 being the most common, followed by trisomies 22 and 21), polyploidy, and monosomy X (45,X)—account for >50% of first-trimester losses.

                    THE CLINICAL SPECTRUM OF SPONTANEOUS ABORTION

   Classification      Cervical Os   Vaginal Bleeding    Uterine Cramping   Ultrasound Findings / POC
   ════════════════════════════════════════════════════════════════════════════════════════════════════
   Threatened          CLOSED        Present (Light to   Mild or Absent     Viable embryo with
   Abortion                          Moderate)                              detectable cardiac activity
   
   Inevitable          DILATED /     Present (Moderate   Moderate to        Non-viable gestation or active
   Abortion            OPEN          to Heavy)           Severe             membrane rupture; no POC passed
   
   Incomplete          DILATED /     Present (Heavy,     Severe             Heterogeneous retained POC
   Abortion            OPEN          with tissue passage)                   present within endometrial cavity
   
   Complete            CLOSED        Decreasing /        Subsided /         Empty uterus; regular, thin
   Abortion                          Minimal             Minimal            endometrial stripe (<5-10 mm)
   
   Missed              CLOSED        Absent or           Absent or          Retained non-viable embryo;
   Abortion                          Minimal Spotting    Minimal            no fetal heart tone (FHT)
   
   Septic              OPEN or       Purulent, Foul      Severe Pelvic      Retained POC or endometritis;
   Abortion            CLOSED        Discharge           Cramping/Tenderness uterine tenderness, fever, chills
   ════════════════════════════════════════════════════════════════════════════════════════════════════

Strict Sonographic Diagnostic Criteria for Pregnancy Failure

According to the American College of Obstetricians and Gynecologists (ACOG) and Society of Radiologists in Ultrasound guidelines, early pregnancy loss is definitively diagnosed when TVUS demonstrates:

1. Crown-Rump Length (CRL) >= 7 mm without visible embryonic cardiac motion;
2. Mean Sac Diameter (MSD) >= 25 mm without an identifiable embryo;
3. Absence of an embryo with a heartbeat >= 14 days after an initial scan demonstrating a gestational sac without a yolk sac;
4. Absence of an embryo with a heartbeat >= 11 days after an initial scan demonstrating a gestational sac with a yolk sac.

---

Clinical Management of Early Pregnancy Loss

For patients with confirmed, non-viable first-trimester early pregnancy loss (incomplete, complete, or missed abortion) who are clinically stable without infection, three management strategies are available: expectant, medical, and surgical.

1. Expectant Management

• Mechanism: Allowing spontaneous uterine contractions to naturally expel the retained gestational tissue.
• Suitability: Most successful in first-trimester incomplete abortion (success rate >70% to 80% within 1 to 2 weeks); significantly lower success rate in missed abortion (<50%). Limited to stable patients with gestation <10 to 12 weeks.
• Duration: Typically observed for up to 14 to 28 days. If spontaneous expulsion does not occur within this window or if excessive hemorrhage develops, active medical or surgical management is initiated.

2. Medical Management

• The Evidence-Based Combination Regimen:
  • Mifepristone 200 mg orally in a single dose, followed 24 hours later by Misoprostol 800 mcg buccally (or vaginally).
  • Mechanism: Mifepristone is a synthetic 19-norsteroid that competitively antagonizes the progesterone receptor, causing decidual necrosis, cervical softening, and sensitization of the myometrium to prostaglandin stimulation. Misoprostol is a synthetic prostaglandin E1 (PGE1) analogue that induces strong myometrial contractions and cervical dilation.
  • Superiority: The landmark Mifepristone Pretreatment Trial (ACOG practice bulletin) demonstrated that pretreatment with oral mifepristone prior to misoprostol achieves complete pregnancy expulsion in 84% to 91% of patients, compared to only 67% with misoprostol monotherapy alone.
• Patient Counseling & Anticipatory Guidance:
  • Cramping and heavy bleeding typically begin within 2 to 4 hours after misoprostol administration, peaking during tissue expulsion.
  • Prescribe scheduled NSAIDs (ibuprofen 600-800 mg PO q8h) and provide rescue oral opioids (oxycodone/acetaminophen) for severe cramping.
  • Red Flag Return Precautions: Immediate emergency evaluation is required if the patient soaks through >= 2 full-sized maxi pads per hour for 2 consecutive hours, passes blood clots larger than a lemon, develops fever >38.0°C (>100.4°F), or experiences severe pelvic pain unresponsive to analgesics.

3. Surgical Management

• Techniques: Manual Vacuum Aspiration (MVA) in the outpatient clinic setting under local paracervical block, or Electric Suction Curettage in the operating suite.
• Absolute Indications: Hemodynamic instability, active uncontrolled uterine hemorrhage, suspected septic abortion, concurrent severe medical comorbidities (severe coagulopathy, cardiovascular disease), or patient preference for immediate, definitive resolution.
• Advantage: Achieves >98% to 99% immediate complete clearance without prolonged bleeding.

4. Septic Abortion Emergency Management

[!CAUTION] SEPTIC ABORTION IS A LIFE-THREATENING EMERGENCY Septic abortion arises from polymicrobial ascending intrauterine infection of retained necrotic products of conception, often involving coliforms, group B streptococci, anaerobes (Bacteroides, Peptostreptococcus), and rarely Clostridium perfringens.

Clinical presentation features high fevers, chills, profuse malodorous or purulent cervical discharge, extreme uterine and cervical motion tenderness, and rapid evolution into septic shock and disseminated intravascular coagulation (DIC).

• Emergency Protocol:
  1. Obtain immediate blood cultures (2 sets) and cervical cultures;
  2. Initiate immediate aggressive intravenous crystalloid resuscitation;
  3. Administer immediate broad-spectrum intravenous triple antibiotics:
     • Ampicillin 2 g IV every 6 hours PLUS Gentamicin 5 mg/kg IV daily PLUS Clindamycin 900 mg IV every 8 hours (or Metronidazole 500 mg IV q8h);
     • Alternative: Ampicillin-Sulbactam 3 g IV q6h OR Piperacillin-Tazobactam 3.375-4.5 g IV q6h;
  4. Perform Emergent Surgical Uterine Evacuation (Suction D&C): Uterine evacuation must never be delayed waiting for antibiotics to "take effect." The infected, necrotic intrauterine nidus must be removed within 2 to 4 hours of antibiotic initiation to arrest the source of endotoxin release.

Rh(D) Alloimmunization Prophylaxis in Early Pregnancy Loss

Fetomaternal hemorrhage can occur during any first-trimester bleeding episode, spontaneous abortion, induced termination, ectopic pregnancy, or uterine instrumental evacuation. If an Rh(D)-negative, non-sensitized mother is exposed to Rh(D)-positive fetal erythrocytes, her immune system produces anti-D immunoglobulins (alloimmunization). In subsequent pregnancies, maternal anti-D IgG antibodies readily cross the placenta, bind fetal red blood cells, and trigger life-threatening hemolytic disease of the fetus and newborn (HDFN), erythroblastosis fetalis, and hydrops fetalis.

                  RH(D) IMMUNE GLOBULIN (RHOGAM) DOSING PROTOCOL

   Gestational Age at Event       Recommended Dose of Rh(D) Immune Globulin     Timing of Administration
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════
   < 12 0/7 Weeks Gestation       50 mcg (Microdose) Intramuscularly*           Within 72 HOURS of event
   
   >= 12 0/7 Weeks Gestation      300 mcg (Standard Dose) Intramuscularly       Within 72 HOURS of event
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════
   *Note: If the 50 mcg microdose formulation is not immediately available, the standard 300 mcg
   vial can be administered safely at any gestational age without adverse effects.

Clinical Execution Mandates

• Window of Administration: Rh(D) immune globulin must be administered within 72 hours of the onset of vaginal bleeding or operative uterine intervention.
• Late Administration: If the 72-hour window has lapsed, the dose should still be administered as soon as recognized up to 28 days post-exposure, as partial protection may still be conferred.
• Who Requires Rh(D) Prophylaxis?: All pregnant women who are Rh(D)-negative and have a negative indirect Coombs test (unsensitized) presenting with:
  1. First-trimester vaginal bleeding (threatened abortion);
  2. Confirmed spontaneous abortion (incomplete, complete, missed);
  3. Ectopic pregnancy (medical or surgical management);
  4. Induced abortion (medical or aspiration);
  5. Transchorionic procedures (chorionic villus sampling) or abdominal trauma.